secwatch.observer — SEC 8-K summary
======================================

Issuer:     ArriVent BioPharma, Inc. (AVBP)
CIK:        0001868279
Form:       8-K
Filed at:   2026-10-06T12:07:09+00:00
Accession:  0001104659-26-113898
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

ArriVent's Phase 3 FURVENT trial misses primary PFS endpoint; firmonertinib 240mg PFS 11.0 vs 9.5 months (p=0.0654)
--------------------------------------------------------------------------------

- FURVENT Phase 3 trial of firmonertinib in first-line EGFR exon 20 insertion NSCLC missed primary endpoint of PFS by BICR: 240mg 11.0 months vs control 9.5 months, p=0.0654, HR 0.75.
- 160mg arm median PFS 8.4 months, HR 0.91; investigator-assessed PFS 11.1 vs 8.3 vs 7.1 months, HR 0.61 (0.46, 0.81) for 240mg vs control.
- Confirmed ORR by BICR: 60% for firmonertinib 240mg, 35% for 160mg, 33% for control; investigator-assessed ORR 61%, 41%, 28%.
- Safety consistent with prior studies, no new signals; Grade >=3 TEAEs 52% (240mg), 53% (160mg), 55% (control); Grade >=3 TRAEs 26%, 22%, 40%.
- CEO Bing Yao called the results 'disappointing'; ArriVent says it is evaluating the full FURVENT dataset to determine the most appropriate development path for firmonertinib.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1868279/000110465926113898/0001104659-26-113898-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1868279/000110465926113898/tm2627092d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-113898

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer